Akari Therapeutics (AKTX)
(Delayed Data from NSDQ)
$1.19 USD
-0.01 (-0.42%)
Updated Apr 26, 2024 03:59 PM ET
3-Hold of 5 3
F Value B Growth NA Momentum NA VGM
Balance Sheet
Fiscal Year End for Akari Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 13 | 9 | 14 | 6 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 1 |
Total Current Assets | 4 | 14 | 12 | 15 | 7 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 4 | 14 | 12 | 15 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 3 | 3 | 2 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 8 | 0 | 0 | 0 |
Total Current Liabilities | 5 | 12 | 5 | 5 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 12 | 6 | 5 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 0 | 0 | 32 |
Capital Surplus | 175 | 167 | 153 | 140 | 111 |
Retained Earnings | -227 | -217 | -200 | -182 | -144 |
Other Equity | 51 | 51 | 52 | 52 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 0 | 2 | 6 | 9 | -2 |
Total Liabilities & Shareholder's Equity | 4 | 14 | 12 | 15 | 7 |
Total Common Equity | 0 | 2 | 6 | 9 | -2 |
Shares Outstanding | 6.60 | 3.70 | 2.60 | 1.90 | 0.70 |
Book Value Per Share | -0.03 | 0.48 | 2.13 | 4.94 | -2.53 |
Fiscal Year End for Akari Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | -99,999 | -99,992 | -99,999 |
Receivables | NA | 0 | NA | NA | NA |
Notes Receivable | NA | 0 | NA | NA | NA |
Inventories | NA | 0 | NA | NA | NA |
Other Current Assets | NA | 1 | NA | 1 | NA |
Total Current Assets | NA | 4 | NA | 8 | NA |
Net Property & Equipment | NA | 0 | NA | NA | NA |
Investments & Advances | NA | 0 | NA | NA | NA |
Other Non-Current Assets | NA | 0 | NA | NA | NA |
Deferred Charges | NA | 0 | NA | NA | NA |
Intangibles | NA | 0 | NA | 0 | NA |
Deposits & Other Assets | NA | 0 | NA | NA | NA |
Total Assets | NA | 4 | NA | 8 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | NA | NA |
Accounts Payable | NA | 2 | NA | 1 | NA |
Current Portion Long-Term Debt | NA | 0 | NA | NA | NA |
Current Portion Capital Leases | NA | 0 | NA | NA | NA |
Accrued Expenses | NA | 2 | NA | 2 | NA |
Income Taxes Payable | NA | 0 | NA | NA | NA |
Other Current Liabilities | NA | 1 | NA | 2 | NA |
Total Current Liabilities | NA | 5 | NA | 5 | NA |
Mortgages | NA | 0 | NA | NA | NA |
Deferred Taxes/Income | NA | 0 | NA | NA | NA |
Convertible Debt | NA | 0 | NA | NA | NA |
Long-Term Debt | NA | 0 | NA | NA | NA |
Non-Current Capital Leases | NA | 0 | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | 0 | NA | |
Minority Interest (Liabilities) | NA | 0 | NA | NA | NA |
Total Liabilities | NA | 5 | NA | 5 | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | NA | NA |
Common Stock (Par) | NA | 1 | NA | 1 | NA |
Capital Surplus | NA | 175 | NA | 171 | NA |
Retained Earnings | NA | -227 | NA | -220 | NA |
Other Equity | NA | 51 | NA | 51 | NA |
Treasury Stock | NA | 0 | NA | NA | NA |
Total Shareholder's Equity | NA | 0 | NA | 3 | NA |
Total Liabilities & Shareholder's Equity | NA | 4 | NA | 8 | NA |
Total Common Equity | 0 | 0 | 0 | 100,002 | 0 |
Shares Outstanding | 7.90 | 6.60 | 5.60 | 3.70 | 3.70 |
Book Value Per Share | 0.00 | -0.03 | 0.00 | 27,027.51 | 0.00 |